{"id":"https://openalex.org/W4246070374","doi":"https://doi.org/10.1097/mol.0b013e3283613a3d","title":"PCSK9 inhibitors","display_name":"PCSK9 inhibitors","alternate_titles":[],"publication_year":2013,"publication_date":"2013-05-07","ids":{"openalex":"https://openalex.org/W4246070374","doi":"https://doi.org/10.1097/mol.0b013e3283613a3d","pmid":"https://pubmed.ncbi.nlm.nih.gov/23652470"},"language":"en","primary_location":{"id":"doi:10.1097/mol.0b013e3283613a3d","doi":"https://doi.org/10.1097/mol.0b013e3283613a3d","is_oa":false,"landing_page_url":"https://doi.org/10.1097/mol.0b013e3283613a3d","pdf_url":null,"source":{"id":"https://openalex.org/S203964698","display_name":"Current Opinion in Lipidology","issn_l":"0957-9672","issn":["0957-9672","1473-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Lipidology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4246070374"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037200495","display_name":"Michel Farnier","orcid":"https://orcid.org/0000-0002-0349-7978","observed_orcids":["https://orcid.org/0000-0002-0349-7978"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Michel Farnier","raw_affiliation_strings":["Department of Lipidology, Point Medical, Dijon, France. michelfarnier@nerim.net","Department of Lipidology, Point Medical, Dijon, France","e-mail: [email\u00a0protected]","fax: +33 3 80 70 38 14","to Michel Farnier, Point Medical, Rond-Point de la Nation, 21000 DIJON, France. Tel: +33 3 80 70 38 13"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lipidology, Point Medical, Dijon, France. michelfarnier@nerim.net","institution_ids":[]},{"raw_affiliation_string":"Department of Lipidology, Point Medical, Dijon, France","institution_ids":[]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +33 3 80 70 38 14","institution_ids":[]},{"raw_affiliation_string":"to Michel Farnier, Point Medical, Rond-Point de la Nation, 21000 DIJON, France. Tel: +33 3 80 70 38 13","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5037200495"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.5487,"has_fulltext":false,"cited_by_count":46,"citation_normalized_percentile":{"value":0.82352941,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"24","issue":"3","first_page":"251","last_page":"258"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/pcsk9","display_name":"PCSK9","score":0.8510000109672546},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9589999914169312},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.6990000009536743},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.8690000176429749},{"id":"https://openalex.org/keywords/familial-hypercholesterolemia","display_name":"familial hypercholesterolemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/statin-intolerance","display_name":"statin intolerance","score":0.972000002861023},{"id":"https://openalex.org/keywords/gene-silencing","display_name":"gene silencing","score":0.8429999947547913},{"id":"https://openalex.org/keywords/atherogenic-lipoproteins","display_name":"atherogenic lipoproteins","score":0.949999988079071},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8560000061988831}],"concepts":[{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.4388962984085083},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3968488276004791},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1327710747718811},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.0729767382144928},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.06760838627815247},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000071449","descriptor_name":"Proprotein Convertase 9","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006938","descriptor_name":"Hyperlipoproteinemia Type II","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006938","descriptor_name":"Hyperlipoproteinemia Type II","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011973","descriptor_name":"Receptors, LDL","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D011973","descriptor_name":"Receptors, LDL","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D011973","descriptor_name":"Receptors, LDL","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012697","descriptor_name":"Serine Endopeptidases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D012697","descriptor_name":"Serine Endopeptidases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015870","descriptor_name":"Gene Expression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D043484","descriptor_name":"Proprotein Convertases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D043484","descriptor_name":"Proprotein Convertases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D043484","descriptor_name":"Proprotein Convertases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D050356","descriptor_name":"Lipid Metabolism","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/mol.0b013e3283613a3d","doi":"https://doi.org/10.1097/mol.0b013e3283613a3d","is_oa":false,"landing_page_url":"https://doi.org/10.1097/mol.0b013e3283613a3d","pdf_url":null,"source":{"id":"https://openalex.org/S203964698","display_name":"Current Opinion in Lipidology","issn_l":"0957-9672","issn":["0957-9672","1473-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Lipidology","raw_type":"journal-article"},{"id":"pmid:23652470","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23652470","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in lipidology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320316238","display_name":"Kowa Company","ror":"https://ror.org/009z2z347"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":51,"referenced_works":["https://openalex.org/W73177875","https://openalex.org/W162053157","https://openalex.org/W206929045","https://openalex.org/W1923289550","https://openalex.org/W1964279010","https://openalex.org/W1965676778","https://openalex.org/W1976691226","https://openalex.org/W1979234333","https://openalex.org/W1987486422","https://openalex.org/W1989730880","https://openalex.org/W1990298974","https://openalex.org/W2040612932","https://openalex.org/W2041941938","https://openalex.org/W2042858467","https://openalex.org/W2043461445","https://openalex.org/W2054610237","https://openalex.org/W2062062360","https://openalex.org/W2064994526","https://openalex.org/W2067539811","https://openalex.org/W2078669364","https://openalex.org/W2085237214","https://openalex.org/W2088358411","https://openalex.org/W2094222285","https://openalex.org/W2096075279","https://openalex.org/W2101979622","https://openalex.org/W2102467926","https://openalex.org/W2103487568","https://openalex.org/W2103518970","https://openalex.org/W2103647780","https://openalex.org/W2106285889","https://openalex.org/W2108493094","https://openalex.org/W2108956796","https://openalex.org/W2110083155","https://openalex.org/W2110227562","https://openalex.org/W2110619762","https://openalex.org/W2117900284","https://openalex.org/W2119708151","https://openalex.org/W2126229169","https://openalex.org/W2127445212","https://openalex.org/W2128030263","https://openalex.org/W2136295087","https://openalex.org/W2138544596","https://openalex.org/W2143546514","https://openalex.org/W2146660254","https://openalex.org/W2148577580","https://openalex.org/W2151731574","https://openalex.org/W2156299572","https://openalex.org/W2163488353","https://openalex.org/W2247997571","https://openalex.org/W2595873267","https://openalex.org/W6608408980"],"related_works":["https://openalex.org/W2063942289","https://openalex.org/W1837311010","https://openalex.org/W4391251010","https://openalex.org/W2396713359","https://openalex.org/W2105872402","https://openalex.org/W2098570565","https://openalex.org/W2563888771","https://openalex.org/W2475212815","https://openalex.org/W2086942972","https://openalex.org/W3208552554"],"abstract_inverted_index":{"PURPOSE":[0],"OF":[1],"REVIEW:":[2],"To":[3],"summarize":[4],"the":[5,14,32,180],"therapeutic":[6],"strategies":[7],"to":[8,12,48,99,110,124,138,155,176],"inhibit":[9],"PCSK9":[10,36,46,67,166],"and":[11,21,83,97,141,149,183],"describe":[13],"main":[15],"results":[16],"obtained":[17],"in":[18,79,106,122,126,134,142,160,171],"phase":[19,86,162,173],"I":[20],"II":[22,163],"trials":[23],"with":[24,61,129,136],"monoclonal":[25,52,77,90,153],"antibodies":[26,78,91,154],"targeting":[27],"PCSK9.":[28],"RECENT":[29],"FINDINGS:":[30],"Among":[31],"various":[33],"approaches":[34],"for":[35,43],"inhibition,":[37],"human":[38],"data":[39],"are":[40,81,94,168],"only":[41],"available":[42],"inhibition":[44,65],"of":[45,66,151,186],"binding":[47],"LDL":[49,107],"receptor":[50],"by":[51,69],"antibodies.":[53],"Promising":[54],"preclinical":[55],"studies":[56,175],"have":[57,157],"also":[58],"been":[59,118,158],"reported":[60],"other":[62],"strategies,":[63],"including":[64],"synthesis":[68],"gene":[70],"silencing":[71],"agents.":[72],"The":[73,115,145],"two":[74,89,152],"most":[75],"advanced":[76],"development":[80],"SAR236553/REGN727":[82],"AMG145.":[84],"In":[85],"II,":[87],"these":[88],"administered":[92],"subcutaneously":[93],"well":[95],"tolerated":[96],"effective":[98],"decrease":[100,105],"atherogenic":[101],"lipoproteins.":[102],"A":[103],"dramatic":[104],"cholesterol":[108],"up":[109],"70%":[111],"can":[112],"be":[113],"obtained.":[114],"efficacy":[116,185],"has":[117],"evaluated":[119],"so":[120],"far":[121],"addition":[123],"statins":[125],"hypercholesterolemic":[127],"patients":[128,135],"or":[130],"without":[131],"familial":[132],"hypercholesterolemia,":[133],"intolerance":[137],"statin":[139],"therapy":[140],"monotherapy.":[143],"SUMMARY:":[144],"short-term":[146],"efficacy,":[147],"safety":[148,182],"tolerability":[150],"PSCK9":[156],"demonstrated":[159],"several":[161],"trials.":[164],"These":[165],"inhibitors":[167],"now":[169],"tested":[170],"larger":[172],"III":[174],"provide":[177],"insights":[178],"into":[179],"long-term":[181],"clinical":[184],"this":[187],"very":[188],"promising":[189],"approach.":[190]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4246070374","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-05-12T00:00:00"}
